New Stock News | The Prospectus for Tangji Medical's IPO on the Hong Kong Stock Exchange Has Lapsed

06:43 10/08/2026

Tangji Medical is a medical device company based in China, focusing on providing innovative solutions for the treatment and full-cycle management of metabolic diseases.

Hangzhou Tangji Medical Technology Co., Ltd. (referred to as: Tangji Medical) submitted its Hong Kong stock prospectus on February 9, 2026, which will expire six months later on August 9, 2026. China International Capital Corporation and Caitong International are its joint sponsors at the time of submission. The prospectus reveals that Tangji Medical is a medical device company based in China, focusing on providing innovative solutions for the treatment and full-cycle management of metabolic diseases. The company's strategy has established a product pipeline that includes medical devices and corresponding management products for treating obesity and metabolic diseases. All products are centered on the treatment and management of metabolic diseases, with indications including overweight, obesity, obesity-related MASH, and obesity-related type 2 diabetes.

YIDU TECH (02158) secures an 8.6 million yuan order from the Changzhou campus of Shouer Hospital, with the growth in orders from top three hospitals continuing after reaching a profitability turning point.

JENSCARE-B (09877) expects its mid-term revenue to increase by 385% to 400% year-on-year.

HK Stock Market Move | LAOPU GOLD (06181) surged over 8%, with gold achieving its largest single-week increase of the year. The upcoming second half of the year is expected to catalyze a peak season.

JENSCARE-B (09877) expects its mid-term revenue to increase by 385% to 400% year-on-year.

HK Stock Market Move | LAOPU GOLD (06181) surged over 8%, with gold achieving its largest single-week increase of the year. The upcoming second half of the year is expected to catalyze a peak season.